Jérôme Delotte1, Mariangela Desantis2, Mélanie Frigenza1, Delphine Quaranta1, André Bongain1, Daniel Benchimol2, Jean Marc Bereder3. 1. Service de gynécologie-obstétrique, reproduction et de médecine foetale, Centre hospitalier universitaire de l'Archet II, Université de Nice-Sophia Antipolis, 151, route St Antoine de Ginestière, 06200 Nice, France. 2. Service de chirurgie générale et cancérologie digestive, Centre hospitalier universitaire de l'Archet II, Université de Nice-Sophia Antipolis, 151, route St Antoine de Ginestière, 06200 Nice, France. 3. Service de chirurgie générale et cancérologie digestive, Centre hospitalier universitaire de l'Archet II, Université de Nice-Sophia Antipolis, 151, route St Antoine de Ginestière, 06200 Nice, France. Electronic address: bereder.jm@chu-nice.fr.
Abstract
OBJECTIVE: To investigate the benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of endometrial peritoneal carcinomatosis. STUDY DESIGN: Preoperative, intraoperative and postoperative data were collected prospectively for 13 patients treated in our University hospital. RESULTS: Of the thirteen patients treated, one patient was lost to follow up. Three patients died within the first twelve months of treatment, and two patients died at respectively 12.4 and 19.4 months after the HIPEC procedure. Seven patients are alive, four of them without recurrence, between 1.5 and 124.8 months after surgery. The Peritoneal Cancer Index (PCI) and the Completeness of Cytoreduction-Score (CC-S) are prognostic factors for survival after HIPEC treatment for peritoneal carcinomatosis of endometrial origin. CONCLUSIONS: The significant survival time in selected patients should lead to a study of the management of peritoneal carcinomatosis of endometrial origin in a larger number of cases, and justifies a clinical trial on a larger scale. Crown
OBJECTIVE: To investigate the benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of endometrial peritoneal carcinomatosis. STUDY DESIGN: Preoperative, intraoperative and postoperative data were collected prospectively for 13 patients treated in our University hospital. RESULTS: Of the thirteen patients treated, one patient was lost to follow up. Three patients died within the first twelve months of treatment, and two patients died at respectively 12.4 and 19.4 months after the HIPEC procedure. Seven patients are alive, four of them without recurrence, between 1.5 and 124.8 months after surgery. The Peritoneal Cancer Index (PCI) and the Completeness of Cytoreduction-Score (CC-S) are prognostic factors for survival after HIPEC treatment for peritoneal carcinomatosis of endometrial origin. CONCLUSIONS: The significant survival time in selected patients should lead to a study of the management of peritoneal carcinomatosis of endometrial origin in a larger number of cases, and justifies a clinical trial on a larger scale. Crown
Authors: D Scott McMeekin; Michael W Sill; Joan L Walker; Kathleen N Moore; Steven E Waggoner; Premal H Thaker; Tina Rizack; James S Hoffman; Paula M Fracasso Journal: Gynecol Oncol Date: 2015-05-06 Impact factor: 5.482
Authors: Manuel Gomes David; Naoual Bakrin; Julia Salleron; Marie Christine Kaminsky; Jean Marc Bereder; Jean Jacques Tuech; Kuno Lehmann; Sanket Mehta; Olivier Glehen; Frédéric Marchal Journal: BMC Surg Date: 2022-01-07 Impact factor: 2.102